$3.97
0.10[2.58%]
At close: Apr 17
$3.97
0[0.00%]
After Hours: 4:00PM EDT
Aldeyra Therapeutics
(NASDAQ:ALDX)Aldeyra Therapeutics Stock (NASDAQ:ALDX), Analyst Ratings, Price Targets, Predictions
Aldeyra Therapeutics Inc has a consensus price target of $9.67, established from looking at the 19 latest analyst ratings. The last 3 analyst ratings were released from Oppenheimer, HC Wainwright & Co., and Citigroup on April 3, 2024, April 2, 2024, and October 17, 2023. With an average price target of $9.33 between Oppenheimer, HC Wainwright & Co., and Citigroup, there's an implied 135.10% upside for Aldeyra Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Oppenheimer
HC Wainwright & Co.
Citigroup
Oppenheimer
HC Wainwright & Co.
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Aldeyra Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/03/2024 | ALDX | Buy Now | Aldeyra Therapeutics | $3.97 | 151.89% | Oppenheimer | Francois Brisebois | → $10 | Upgrade | Perform → Outperform | Get Alert |
| 04/02/2024 | ALDX | Buy Now | Aldeyra Therapeutics | $3.97 | 151.89% | HC Wainwright & Co. | Matthew Caufield | → $10 | Reinstates | Buy → Buy | Get Alert |
| 10/17/2023 | ALDX | Buy Now | Aldeyra Therapeutics | $3.97 | 101.51% | Citigroup | Yigal Nochomovitz | $25 → $8 | Maintains | Buy | Get Alert |
| 10/17/2023 | ALDX | Buy Now | Aldeyra Therapeutics | $3.97 | — | Oppenheimer | Justin Kim | — | Downgrade | Outperform → Perform | Get Alert |
| 08/09/2023 | ALDX | Buy Now | Aldeyra Therapeutics | $3.97 | 252.64% | Oppenheimer | Justin Kim | → $14 | Reiterates | Outperform → Outperform | Get Alert |
| 06/30/2023 | ALDX | Buy Now | Aldeyra Therapeutics | $3.97 | 277.83% | HC Wainwright & Co. | Matthew Caufield | → $15 | Reiterates | Buy → Buy | Get Alert |
| 06/22/2023 | ALDX | Buy Now | Aldeyra Therapeutics | $3.97 | 277.83% | HC Wainwright & Co. | Matthew Caufield | → $15 | Reiterates | Buy → Buy | Get Alert |
| 06/16/2023 | ALDX | Buy Now | Aldeyra Therapeutics | $3.97 | 277.83% | HC Wainwright & Co. | Matthew Caufield | → $15 | Reiterates | Buy → Buy | Get Alert |
| 06/01/2023 | ALDX | Buy Now | Aldeyra Therapeutics | $3.97 | 529.72% | Citigroup | Yigal Nochomovitz | $28 → $25 | Maintains | Buy | Get Alert |
| 05/05/2023 | ALDX | Buy Now | Aldeyra Therapeutics | $3.97 | 277.83% | HC Wainwright & Co. | Matthew Caufield | → $15 | Reiterates | → Buy | Get Alert |
| 03/10/2023 | ALDX | Buy Now | Aldeyra Therapeutics | $3.97 | 605.29% | Citigroup | Yigal Nochomovitz | $23 → $28 | Maintains | Buy | Get Alert |
| 03/10/2023 | ALDX | Buy Now | Aldeyra Therapeutics | $3.97 | 277.83% | HC Wainwright & Co. | Matthew Caufield | → $15 | Reiterates | → Buy | Get Alert |
| 03/01/2023 | ALDX | Buy Now | Aldeyra Therapeutics | $3.97 | 277.83% | HC Wainwright & Co. | Matthew Caufield | → $15 | Reiterates | → Buy | Get Alert |
| 11/21/2022 | ALDX | Buy Now | Aldeyra Therapeutics | $3.97 | 479.35% | Citigroup | Yigal Nochomovitz | $26 → $23 | Maintains | Buy | Get Alert |
| 06/09/2022 | ALDX | Buy Now | Aldeyra Therapeutics | $3.97 | 554.91% | Citigroup | Yigal Nochomovitz | $21 → $26 | Maintains | Buy | Get Alert |
| 04/27/2022 | ALDX | Buy Now | Aldeyra Therapeutics | $3.97 | 277.83% | HC Wainwright & Co. | Andrew Fein | → $15 | Assumes | → Buy | Get Alert |
| 12/21/2021 | ALDX | Buy Now | Aldeyra Therapeutics | $3.97 | 428.97% | Citigroup | Yigal Nochomovitz | $25 → $21 | Maintains | Buy | Get Alert |
| 12/21/2021 | ALDX | Buy Now | Aldeyra Therapeutics | $3.97 | 277.83% | SVB Leerink | Marc Goodman | $24 → $15 | Maintains | Outperform | Get Alert |
| 04/28/2021 | ALDX | Buy Now | Aldeyra Therapeutics | $3.97 | 529.72% | Citigroup | Yigal Nochomovitz | $22 → $25 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Aldeyra Therapeutics (ALDX)?
The latest price target for Aldeyra Therapeutics (NASDAQ: ALDX) was reported by Oppenheimer on April 3, 2024. The analyst firm set a price target for $10.00 expecting ALDX to rise to within 12 months (a possible 151.89% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Aldeyra Therapeutics (ALDX)?
The latest analyst rating for Aldeyra Therapeutics (NASDAQ: ALDX) was provided by Oppenheimer, and Aldeyra Therapeutics upgraded their outperform rating.
When was the last upgrade for Aldeyra Therapeutics (ALDX)?
The last upgrade for Aldeyra Therapeutics Inc happened on April 3, 2024 when Oppenheimer raised their price target to $10. Oppenheimer previously had a perform for Aldeyra Therapeutics Inc.
When was the last downgrade for Aldeyra Therapeutics (ALDX)?
The last downgrade for Aldeyra Therapeutics Inc happened on October 17, 2023 when Oppenheimer changed their price target from N/A to N/A for Aldeyra Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Aldeyra Therapeutics (ALDX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aldeyra Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aldeyra Therapeutics was filed on April 3, 2024 so you should expect the next rating to be made available sometime around April 3, 2025.
Is the Analyst Rating Aldeyra Therapeutics (ALDX) correct?
While ratings are subjective and will change, the latest Aldeyra Therapeutics (ALDX) rating was a upgraded with a price target of $0.00 to $10.00. The current price Aldeyra Therapeutics (ALDX) is trading at is $3.97, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.